Heart BMJ

JANUARY 29, 2025

Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aortic valve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aortic stenosis who underwent successful TAVR. Trial registration number ChiCTR2300072300.

Aortic valve 52

Aortic valve Thrombosis Aortic Technology 52

Frontiers in Cardiovascular Medicine

MARCH 9, 2025

Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR. Clinical valve thrombosis is rare.

Aortic valve 52

Aortic valve Aortic TAVR Thrombosis 52

American College of Cardiology

JANUARY 6, 2025

Subclinical leaflet thrombosis (SLT) has raised concerns about the long-term durability and outcomes of transcatheter aortic valve replacement (TAVR). Clinical valve thrombosis (CVT) is a rare complication after TAVR with an incidence of 0.62.8%

Thrombosis 40

Thrombosis TAVR Aortic valve Aortic 40

DAIC

MAY 15, 2024

Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.

Aortic valve 105

Aortic valve TAVR Outcomes Aortic 105

Circulation

NOVEMBER 11, 2024

Introduction:Subclinical leaflet thrombosis is an increasingly recognized complication in patients undergoing transcatheter aortic valve replacement (TAVR). The optimized TAV design could reduce the risk of subclinical leaflet thrombosis in patients undergoing TAVR.

Aortic valve 40

Aortic valve Thrombosis Aortic TAVR 40

Heart BMJ

DECEMBER 20, 2023

Objectives The effect of subclinical leaflet thrombosis, characterised by hypoattenuated leaflet thickening (HALT), on the valve haemodynamic function and durability of the bioprosthetic valve, is not yet determined.

Aortic valve 40

Aortic valve Thrombosis Aortic TAVR 40

Journal of the American Heart Association

FEBRUARY 14, 2025

BackgroundValveinvalve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40